MLXIPL

Across TCGA pan-cancer cohorts, MLXIPL Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MLXIPL data layer compared with 19 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher MLXIPL Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MLXIPL expression acts as an unfavorable survival marker.

BLCA, UCEC, and PRAD are the cancer types where MLXIPL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	IV	0.051	0.600	<.001	36	view →
UCEC	OS	Median	IV	0.133	0.754	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LGG	DFS	Median	All	0.110	0.826	<.001	3	view →
SKCM	OS	Median	IV	0.415	0.861	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MLXIPL–BLCA (OS)

Open the BLCA breakdown →